Search This Blog

Saturday, January 23, 2016

Vectibix® (panitumumab) And Best Supportive Care Improves Overall Survival Compared To Best Supportive Care In Chemorefractory KRAS And RAS Wild-Type Metastatic Colorectal Cancer

First Phase 3 Vectibix Trial to Include a Prespecified Analysis of Efficacy Endpoints by RAS Tumor Status in Primary Analysis
Results Presented at Gastrointestinal Cancers Symposium 2016 Reinforce Importance of RAS Testing


Amgen - Investors - RSS Content
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)